Key Points
- CEO sale: CEO Daniel Barber sold 180,677 shares on March 10 at an average price of $4.17 for total proceeds of $753,423, cutting his stake by 15.24% to 1,004,753 shares (valued ~ $4.19M).
- Weak quarterly results and stock metrics: Aquestive reported a Q loss of $0.26 EPS (vs. -$0.13 est.) and revenue of $13.02M (vs. $13.28M est.), while the stock trades around $4.24 with a market cap of ~$517M and a consensus analyst target of $8.80.
- Risk factors and sentiment: Multiple senior officers disclosed large insider sales and a securities class action has been filed, creating legal/market uncertainty despite mixed analyst coverage and a prevailing "Buy" consensus.
Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) insider Sherry Korczynski sold 15,741 shares of the firm's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $4.17, for a total value of $65,639.97. Following the completion of the sale, the insider owned 241,117 shares of the company's stock, valued at approximately $1,005,457.89. This trade represents a 6.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Aquestive Therapeutics Stock Down 4.3%
NASDAQ:AQST traded down $0.18 during trading hours on Thursday, hitting $4.09. 574,749 shares of the stock were exchanged, compared to its average volume of 5,516,916. The company's 50 day moving average is $4.08 and its two-hundred day moving average is $5.21. The company has a market capitalization of $498.66 million, a P/E ratio of -5.28 and a beta of 1.61. Aquestive Therapeutics, Inc. has a twelve month low of $2.12 and a twelve month high of $7.55.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings results on Wednesday, March 4th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.13). The company had revenue of $13.02 million for the quarter, compared to analyst estimates of $13.28 million. On average, equities research analysts expect that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on the stock. Lake Street Capital set a $6.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, February 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Aquestive Therapeutics in a research report on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of Aquestive Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, March 7th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $8.80.
Read Our Latest Analysis on Aquestive Therapeutics
More Aquestive Therapeutics News
Here are the key news stories impacting Aquestive Therapeutics this week:
- Positive Sentiment: HC Wainwright raised several near‑term EPS estimates and lifted its FY2026 view (less negative) — modest analytical support for the story and potential relief if guidance/progress continues. HC Wainwright Estimates
- Positive Sentiment: Independent coverage remains constructive on Anaphylm: a Seeking Alpha piece reiterates a Buy and argues the CRL issues are addressable (packaging/labeling), forecasting a high approval/adoption probability if the planned PK study succeeds. That supports upside tied to regulatory progress. Seeking Alpha: Anaphylm
- Neutral Sentiment: Short‑interest data in feeds is currently reporting anomalous/zero values (likely data error) and should not be relied on for a short‑squeeze narrative until official reporting clears up. (No reliable link.)
- Negative Sentiment: Multiple law firms and notice filings indicate a securities class action has been filed and several firms are soliciting lead‑plaintiff roles for purchasers from June 16, 2025 to Jan 8, 2026 — this increases legal exposure, potential costs, and investor uncertainty. Representative notices: Bernstein Liebhard, Rosen, Portnoy/others. Bernstein Liebhard Alert Portnoy Notice
- Negative Sentiment: A PRNewswire item highlights a lawsuit alleging an analyst (Cantor) slashed AQST’s price target from $15 to $8 (Jan 9), linking that cut to a >37% one‑day loss for certain holders — adds a contested narrative about analyst conduct and market impact. PR Newswire: Analyst Lawsuit
- Negative Sentiment: Large insider sales were disclosed on March 10 (CEO and multiple senior officers sold sizeable blocks at ~ $4.17), reducing insider ownership materially — often interpreted by markets as a negative signal about near‑term prospects or liquidity needs. Representative SEC filing (CEO): SEC Filing (CEO Sale)
Institutional Trading of Aquestive Therapeutics
Several hedge funds have recently bought and sold shares of AQST. NewEdge Advisors LLC bought a new position in Aquestive Therapeutics in the third quarter valued at approximately $28,000. BNP Paribas Financial Markets increased its position in shares of Aquestive Therapeutics by 78.3% during the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock worth $31,000 after acquiring an additional 4,134 shares in the last quarter. Modern Wealth Management LLC acquired a new stake in shares of Aquestive Therapeutics during the second quarter worth $33,000. Cox Capital Mgt LLC bought a new stake in Aquestive Therapeutics in the 3rd quarter valued at $59,000. Finally, Kestra Private Wealth Services LLC bought a new stake in Aquestive Therapeutics in the 3rd quarter valued at $60,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.
About Aquestive Therapeutics
(
Get Free Report)
Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.
The company's lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
